This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (53)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Report of the Cooperative Breast Cancer Group

Ira S. Goldenberg, MD; M. Nancy Waters; Robert S. Ravdin, MD; Fred J. Ansfield, MD; Albert Segaloff, MD

JAMA. 1973;223(11):1267-1268.

Abstract
A randomized clinical trial of calusterone and testolactone according to the protocol of the Cooperative Breast Cancer Group (CBCG) produced objective remissions of advanced breast cancer in 28% of women receiving calusterone and 18% of those given testolactone. Effectiveness of the calusterone has prompted a dose-response study by the CBCG to determine the most effective dose of this androgen for use in treatment of breast cancer.

Author Affiliations
From the Department of Surgery, Yale University School of Medicine, New Haven, Conn (Dr. Goldenberg); the Clinical Trials Research Center, Louisiana State University Medical Center, New Orleans (Ms. Waters); the University of Pennsylvania School of Medicine, Philadelphia (Dr. Ravdin); the University of Wisconsin School of Medicine, Madison (Dr. Ansfield); and the Alton Ochsner Medical Foundation, New Orleans (Dr. Segaloff). Deceased.

Footnotes
Reprint requests to 333 Cedar St, New Haven, Conn 06510 (Dr. Goldenberg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drugs Five Years Later: Calusterone
BRODKIN and COOPER
ANN INTERN MED 1978;89:945-948.
ABSTRACT